a patient with ASTHMA who is still symptomatic on an ICS/LABA

TRELEGY is NOT for the relief of acute bronchospasm.

Help release her from the bronchoconstriction of ASTHMA

Meet Lucy, a patient with ASTHMA

  • 40-year-old woman
  • Prebronchodilator % predicted FEV1: 70%
  • Diagnosed with asthma 10 years ago
  • Adherent to current treatment with a medium-dose ICS/LABA and as-needed SABA

Hypothetical patient profile.

Lucy Photo
Lucy Photo

Patients like Lucy may experience1:

  • Chest tightness
  • Shortness of breath once a week
  • Nighttime symptoms at least once a week

Could your adult patients with ASTHMA who continue to experience symptoms on an ICS/LABA benefit from once-daily triple therapy with TRELEGY?

Review clinical trial data for TRELEGY vs an ICS/LABA in ASTHMA

Unmet need in ASTHMA

Unmet need in ASTHMA

You may have patients who are still experiencing asthma symptoms

Of patients with asthma treated with a medium- or high-dose ICS/LABA, 30% - 50% reported inadequately controlled asthma (ACT Score of 19 or less), even when treatment adherence was optimal.2-6*

*Based on data from 3 randomized controlled trials (N=2431) and a real-world study (N=428). For the randomized controlled trials, >90% of patients were at least 80% adherent. For the real-world study, only patients with self-reported moderate to high adherence according to the Morisky Medication Adherence Scale were included.2-6


See how much TRELEGY improved lung function in adult patients with ASTHMA.

See head-to-head data


Which component of TRELEGY inhibits bronchoconstriction?

View MOA triple action


What is the starting dose of TRELEGY for adult patients with ASTHMA?

See dosing considerations

Request TRELEGY savings offers for eligible patients & TRELEGY samples.

Learn more